Who are Vir Biotechnology, Inc.'s main suppliers?

Vir Biotechnology, Inc. (VIR) key suppliers include: INSTITUTE-FOR-RESEARCH-IN-BIOMEDICINE, SANOFI-S-A, THE-ROCKEFELLER-UNIVERSITY, Sanofi, Sanofi and 2 more. View the full supplier network at chainsifter.com/chain/VIR.

Who are Vir Biotechnology, Inc.'s major customers?

Vir Biotechnology, Inc. (VIR) key customers include: USGOV-DEPARTMENT-OF-HEALTH-AND-HUMAN-SERVICES, ASTELLAS-US-LLC, NORGINE, GATES-FOUNDATION, Sanofi and 2 more. View the full customer network at chainsifter.com/chain/VIR.

What sector is Vir Biotechnology, Inc. in?

Vir Biotechnology, Inc. (VIR) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

VIR Supply Chain: Vir Biotechnology, Inc. Supplier List & 17 Relationships

7Suppliers

7Customers

3Debt Items

20Related Chains

Vir Biotechnology, Inc. Suppliers

Ticker	Name	Confidence	Evidence
INSTITUTE-FOR-RESEARCH-IN-BIOMEDICINE	INSTITUTE-FOR-RESEARCH-IN-BIOMEDICINE	92%	Under the terms of the IRB Research Agreement, IRB performs certain research activities for Humabs
SANOFI-S-A	SANOFI-S-A	90%	Under the terms of Vir Bio's licensing agreement with Sanofi, Vir Bio will share a portion of certain collaboration proceeds received from Astellas with Sanofi
THE-ROCKEFELLER-UNIVERSITY	THE-ROCKEFELLER-UNIVERSITY	90%	Pursuant to the Rockefeller Agreement, we entered into an exclusive license agreement with The Rockefeller University, or Rockefeller
SNY	Sanofi	72%	Reciprocal relationship from SNY graph: Reciprocal relationship from VIR graph: Reciprocal relationship from SNY graph: Reciprocal relationship from VIR graph: Reciprocal relationship from SNY graph:…
SNYNF	Sanofi	72%	candidates, the competitive position of our product candidates, and import or export of raw materials and product used in our drug development, clinical manufacturing and future commercial activities…
SNYNF	Sanofi	72%	Reciprocal relationship from SNYNF graph: Reciprocal relationship from VIR graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from VIR graph: candidates, the competitive positio…
XNCR	Xencor, Inc.	72%	Reciprocal relationship from XNCR graph: Reciprocal relationship from VIR graph: Reciprocal relationship from XNCR graph: Reciprocal relationship from VIR graph: Reciprocal relationship from XNCR gra…

Vir Biotechnology, Inc. Customers

Ticker	Name	Confidence	Evidence
USGOV-DEPARTMENT-OF-HEALTH-AND-HUMAN-SERVICES	USGOV-DEPARTMENT-OF-HEALTH-AND-HUMAN-SERVICES	95%	USAspending awards from Department of Health and Human Services: $65,867,804 across 1 awards. 75A50122C00081 VIR BIOTECHNOLOGY - OTA FOR PRE-EXPOSURE PROPHYLACTIC MONOCLONAL ANTIBODIES FOR THE PREVEN…
ASTELLAS-US-LLC	ASTELLAS-US-LLC	92%	Vir Bio has agreed to grant to Astellas, subject to certain intellectual property rights of Sanofi S.A. (Sanofi), an exclusive license to develop, manufacture, commercialize and otherwise exploit VIR-5500
NORGINE	NORGINE	92%	The Company determined that Norgine is a customer with respect to the delivery of Norgine License
GATES-FOUNDATION	GATES-FOUNDATION	90%	The Company accounted for the common stock issued to the Gates Foundation based on its fair market value on the closing date
SNYNF	Sanofi	72%	Reciprocal relationship from SNYNF graph: Reciprocal relationship from VIR graph: e of Contents VIR BIOTECHNOLOGY, INC. Notes to Consolidated Financial Statements $ $ Less: Segment expenses (1) Cost …
SNYNF	Sanofi	72%	e of Contents VIR BIOTECHNOLOGY, INC. Notes to Consolidated Financial Statements $ $ Less: Segment expenses (1) Cost of revenue Research and development Personnel (2) Licenses, collaborations and con…
ENCENTRIO-THERAPEUTICS-INC	ENCENTRIO-THERAPEUTICS-INC	62%	n our clinical programs, the ability of collaborators to successfully develop our licensed product candidates, competition, manufacturing capability and commercial viability. In addition, under our l…

Vir Biotechnology, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
VIR-DEBT-13360	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2019-12-31.
VIR-DEBT-13359	Warrants outstanding: 2049000	90%	xbrl warrant detail from xbrl 2019-12-31.
VIR-DEBT	Debt stack $95.6M	90%	Market cache reports total debt of $95.6M.

Vir Biotechnology, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Vir Biotechnology, Inc..

Vir Biotechnology, Inc. Ownership

Holder	Name	Confidence	Evidence
VIR-OWNER-BLACKROCK-INC	BlackRock, Inc.	90%	13F overlay lists BlackRock, Inc. as top holder; 257 tracked holders.

Vir Biotechnology, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops
ATOS	Atossa Therapeutics, Inc.	100.00	2
CALC	CalciMedica, Inc.	100.00	2
EDIT	Editas Medicine, Inc.	100.00	2
CTMX	CytomX Therapeutics, Inc.	100.00	2
REGN	Regeneron Pharmaceuticals, Inc.	100.00	2
ANRO	Alto Neuroscience, Inc.	100.00	2
WHWK	Whitehawk Therapeutics, Inc.	100.00	2
BLRX	BioLineRx Ltd.	100.00	2
CYTK	Cytokinetics, Incorporated	100.00	2
CBIO	Crescent Biopharma, Inc.	100.00	2
ANL	Adlai Nortye Ltd.	100.00	2
ALXO	ALX Oncology Holdings Inc.	100.00	2
CCEP	Coca-Cola Europacific Partners PLC	100.00	2
DSGN	Design Therapeutics, Inc.	100.00	2
AZN	AstraZeneca PLC	100.00	2
CYTOF	Altamira Therapeutics Ltd.	100.00	2
BIOA	BioAge Labs, Inc.	100.00	2
DYN	Dyne Therapeutics, Inc.	100.00	2
DBVTF	DBV TECHNOLOGIES	100.00	2
NVO	Novo Nordisk A/S	100.00	2

Vir Biotechnology, Inc. Supply Chain